FDA Approves Zephyr Endobronchial Valve for Treating Severe Emphysema
REDWOOD CITY, Calif. – June 29, 2018 – Pulmonx® Corp. announced today that the U.S. Food and Drug Administration (FDA) has approved the Zephyr® Endobronchial Valve System for treating severe emphysema patients. The Zephyr Valve is the first minimally-invasive device approved in the United States for
Zephyr Endobronchial Valves Improve Breathing, Quality of Life and Activity for Severe Emphysema Patients in US Pivotal Trial
SAN DIEGO and REDWOOD CITY, Calif. – May 22, 2018 – Pulmonx® Corp. today announced positive one-year results from the U.S. LIBERATE pivotal trial of the Zephyr® Endobronchial Valve, a minimally-invasive treatment for severe emphysema, an advanced form of chronic obstructive pulmonary disease (COPD)….
Pulmonx Submits Premarket Approval (PMA) Application to U.S. FDA for Zephyr Endobronchial Valve as Treatment for Emphysema
Zephyr EBVs are the Only Minimally-Invasive, Removable Devices for Emphysema with Validated Diagnostic Tool to Select Patients Likely to Benefit from Treatment